MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines

MicroRNAs (miRNAs) regulate gene expression post-transcriptionally. In this way they might influence whether a cell is sensitive or resistant to a certain drug. So far, only a limited number of relatively small scale studies comprising few cell lines and/or drugs have been performed. To obtain a broader view on miRNAs and their association with drug response, we investigated the expression levels of 411 miRNAs in relation to drug sensitivity in 36 breast cancer cell lines. For this purpose IC50 values of a drug screen involving 34 drugs were associated with miRNA expression data of the same breast cancer cell lines. Since molecular subtype of the breast cancer cell lines is considered a confounding factor in drug association studies, multivariate analysis taking subtype into account was performed on significant miRNA-drug associations which retained 13 associations. These associations consisted of 11 different miRNAs and eight different drugs (among which Paclitaxel, Docetaxel and Veliparib). The taxanes, Paclitaxel and Docetaxel, were the only drugs having miRNAs in common: hsa-miR-187-5p and hsa-miR-106a-3p indicative of drug resistance while Paclitaxel sensitivity alone associated with hsa-miR-556-5p. Tivantinib was associated with hsa-let-7d-5p and hsa-miR-18a-5p for sensitivity and hsa-miR-637 for resistance. Drug sensitivity was associated with hsa-let-7a-5p for Bortezomib, hsa-miR-135a-3p for JNJ-707 and hsa-miR-185-3p for Panobinostat. Drug resistance was associated with hsa-miR-182-5p for Veliparib and hsa-miR-629-5p for Tipifarnib. Pathway analysis for significant miRNAs was performed to reveal biological roles, aiding to find a potential mechanistic link for the observed associations with drug response. By doing so hsa-miR-187-5p was linked to the cell cycle G2-M checkpoint in line with this checkpoint being the target of taxanes. In conclusion, our study shows that miRNAs could potentially serve as biomarkers for intrinsic drug resistance and that pathway analyses can provide additional information in this context.

[1]  C. Wallington-Beddoe,et al.  Resistance to proteasome inhibitors and other targeted therapies in myeloma , 2018, British journal of haematology.

[2]  M. Reagan,et al.  Soluble and Cell–Cell-Mediated Drivers of Proteasome Inhibitor Resistance in Multiple Myeloma , 2018, Front. Endocrinol..

[3]  W. Guo,et al.  Primate‐specific miRNA‐637 inhibited tumorigenesis in human pancreatic ductal adenocarcinoma cells by suppressing Akt1 expression , 2018, Experimental cell research.

[4]  Kian Behbakht,et al.  PARP inhibitors: Clinical utility and possibilities of overcoming resistance. , 2017, Gynecologic oncology.

[5]  Y. Li,et al.  The EGFR/miR-338-3p/EYA2 axis controls breast tumor growth and lung metastasis , 2017, Cell Death & Disease.

[6]  N. Shomron,et al.  MicroRNA regulation of progesterone receptor in breast cancer , 2017, Oncotarget.

[7]  N. Pyrsopoulos,et al.  Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date , 2016, Journal of Hepatocellular Carcinoma.

[8]  M. Fabbri,et al.  MicroRNAs and cancer resistance: A new molecular plot , 2016, Clinical pharmacology and therapeutics.

[9]  G. Di Trapani,et al.  TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-кβ inhibition , 2016, Cell cycle.

[10]  Hinrich W. H. Göhlmann,et al.  Understanding drugs in breast cancer through drug sensitivity screening , 2015, SpringerPlus.

[11]  Young-Kook Kim,et al.  Extracellular microRNAs as Biomarkers in Human Disease , 2015, Chonnam medical journal.

[12]  S. Hammond.  An overview of microRNAs. , 2015, Advanced drug delivery reviews.

[13]  Qing Yu,et al.  Let-7 miRNAs Modulate the Activation of NF-κB by Targeting TNFAIP3 and Are Involved in the Pathogenesis of Lupus Nephritis , 2015, PloS one.

[14]  R. Gregory,et al.  MicroRNA biogenesis pathways in cancer , 2015, Nature Reviews Cancer.

[15]  M. Zavolan,et al.  Identification and consequences of miRNA–target interactions — beyond repression of gene expression , 2014, Nature Reviews Genetics.

[16]  J. Schellens,et al.  Cellular and clinical pharmacology of the taxanes docetaxel and paclitaxel – a review , 2014, Anti-cancer drugs.

[17]  Chia-Hung Chen,et al.  Lapatinib–induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors , 2013, BMC Genomics.

[18]  X. Chen,et al.  Stat3-coordinated Lin-28–let-7–HMGA2 and miR-200–ZEB1 circuits initiate and maintain oncostatin M-driven epithelial–mesenchymal transition , 2013, Oncogene.

[19]  M. Wood,et al.  Epigenetics and ncRNAs in Brain Function and Disease: Mechanisms and Prospects for Therapy , 2013, Neurotherapeutics.

[20]  A. Ashworth,et al.  Identification of miRNA modulators to PARP inhibitor response. , 2013, DNA repair.

[21]  Burton B. Yang,et al.  Friend or foe: the role of microRNA in chemotherapy resistance , 2013, Acta Pharmacologica Sinica.

[22]  J. Foekens,et al.  miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs , 2013, Breast Cancer Research.

[23]  M. Kuroda,et al.  MicroRNA-18a modulates STAT3 activity through negative regulation of PIAS3 during gastric adenocarcinogenesis , 2013, British Journal of Cancer.

[24]  Charles Theillet,et al.  Estrogen and retinoic acid antagonistically regulate several microRNA genes to control aerobic glycolysis in breast cancer cells. , 2012, Molecular bioSystems.

[25]  C. Croce,et al.  MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review , 2012, EMBO molecular medicine.

[26]  Carmen Birchmeier,et al.  Targeting MET in cancer: rationale and progress , 2012, Nature Reviews Cancer.

[27]  C. Croce,et al.  MicroRNAs in the pathogenesis of cancer. , 2011, Seminars in oncology.

[28]  D. Xie,et al.  Primate‐specific microRNA‐637 inhibits tumorigenesis in hepatocellular carcinoma by disrupting signal transducer and activator of transcription 3 signaling , 2011, Hepatology.

[29]  Ming-Sound Tsao,et al.  An overview of the c-MET signaling pathway , 2011, Therapeutic advances in medical oncology.

[30]  A. Tutt,et al.  PARP inhibitors--current status and the walk towards early breast cancer. , 2011, Breast.

[31]  G. Calin,et al.  MicroRNAs in body fluids—the mix of hormones and biomarkers , 2011, Nature Reviews Clinical Oncology.

[32]  E. Izaurralde,et al.  Gene silencing by microRNAs: contributions of translational repression and mRNA decay , 2011, Nature Reviews Genetics.

[33]  M. Gorospe,et al.  miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. , 2011, Molecular cell.

[34]  A. Younes,et al.  Histone deacetylase inhibitors in the treatment of lymphoma. , 2010, Discovery medicine.

[35]  W. Filipowicz,et al.  The widespread regulation of microRNA biogenesis, function and decay , 2010, Nature Reviews Genetics.

[36]  Nicholas T. Ingolia,et al.  Mammalian microRNAs predominantly act to decrease target mRNA levels , 2010, Nature.

[37]  S. Jeay,et al.  ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity , 2010, Molecular Cancer Therapeutics.

[38]  Päivi Heikkilä,et al.  Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies , 2010, PLoS medicine.

[39]  P. Guyre,et al.  Estradiol Suppresses NF-κB Activation through Coordinated Regulation of let-7a and miR-125b in Primary Human Macrophages , 2010, The Journal of Immunology.

[40]  Hans Clevers,et al.  Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines , 2010, Breast Cancer Research and Treatment.

[41]  P. Fisher,et al.  Histone Deacetylase Inhibitors Activate NF-κB in Human Leukemia Cells through an ATM/NEMO-related Pathway* , 2010, The Journal of Biological Chemistry.

[42]  W. V. van IJcken,et al.  MicroRNA‐mediated gene silencing modulates the UV‐induced DNA‐damage response , 2009, The EMBO journal.

[43]  Bob Löwenberg,et al.  A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia. , 2007, Blood.

[44]  M. Botta,et al.  Paclitaxel And Docetaxel Resistance: Molecular Mechanisms and Development of New Generation Taxanes , 2007, ChemMedChem.

[45]  E. Wiemer.  The role of microRNAs in cancer: no small matter. , 2007, European journal of cancer.

[46]  David C. Atkins,et al.  Identification of Molecular Predictors of Response in a Study of Tipifarnib Treatment in Relapsed and Refractory Acute Myelogenous Leukemia , 2007, Clinical Cancer Research.

[47]  S. Vacher,et al.  Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. , 2006, Endocrine-related cancer.

[48]  Stijn van Dongen,et al.  miRBase: microRNA sequences, targets and gene nomenclature , 2005, Nucleic Acids Res..

[49]  Mieke Timmermans,et al.  How ADAM-9 and ADAM-11 Differentially From Estrogen Receptor Predict Response to Tamoxifen Treatment in Patients with Recurrent Breast Cancer: a Retrospective Study , 2005, Clinical Cancer Research.

[50]  Clifford A. Meyer,et al.  Chromosome-Wide Mapping of Estrogen Receptor Binding Reveals Long-Range Regulation Requiring the Forkhead Protein FoxA1 , 2005, Cell.

[51]  Syed Mohsin,et al.  Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  John D. Storey,et al.  Statistical significance for genomewide studies , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[53]  R. Tibshirani,et al.  Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[54]  P. Norman.  Tipifarnib (Janssen Pharmaceutica). , 2002, Current opinion in investigational drugs.

[55]  C Caldas,et al.  Molecular cytogenetic analysis of breast cancer cell lines , 2000, British Journal of Cancer.

[56]  P. Elliott,et al.  Proteasome inhibition measurements: clinical application. , 2000, Clinical chemistry.

[57]  O. Kallioniemi,et al.  Molecular cytogenetic analysis of 11 new breast cancer cell lines , 1999, British Journal of Cancer.

[58]  M. Westerfield,et al.  Characterization of paired tumor and non‐tumor cell lines established from patients with breast cancer , 1998, International journal of cancer.

[59]  J. Bergh,et al.  Homozygous deletions at 3p12 in breast and lung cancer , 1998, Oncogene.

[60]  J. Minna,et al.  Characterization of a breast cancer cell line derived from a germ-line BRCA1 mutation carrier. , 1998, Cancer research.

[61]  J. Sloane,et al.  The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. , 1997, Cancer research.

[62]  J. Minna,et al.  Analysis of the FHIT gene and FRA3B region in sporadic breast cancer, preneoplastic lesions, and familial breast cancer probands. , 1997, Cancer research.

[63]  S. Ethier,et al.  erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line. , 1996, Cancer research.

[64]  Y. Chung,et al.  [Establishment and characterization of a human breast cancer cell line, OCUB-1]. , 1994, Human cell.

[65]  B. Weber,et al.  Differential isolation of normal luminal mammary epithelial cells and breast cancer cells from primary and metastatic sites using selective media. , 1993, Cancer research.

[66]  P. Meltzer,et al.  Establishment of two new cell lines derived from human breast carcinomas with HER-2/neu amplification. , 1991, British Journal of Cancer.

[67]  S. Dairkee,et al.  Immortalization in culture: occurrence at a late stage in the progression of breast cancer. , 1987, Journal of the National Cancer Institute.

[68]  H. J. Evans,et al.  Advances in Cancer Research , 1985, British Journal of Cancer.

[69]  M. Radu,et al.  Establishment and characterization of a cell line of human breast carcinoma origin. , 1979, European journal of cancer.

[70]  M. Olivé,et al.  Long-term human breast carcinoma cell lines of metastatic origin: Preliminary characterization , 1978, In Vitro.

[71]  E. Lasfargues,et al.  Isolation of two human tumor epithelial cell lines from solid breast carcinomas. , 1978, Journal of the National Cancer Institute.

[72]  E. L. Springer,et al.  Two syngeneic cell lines from human breast tissue: the aneuploid mammary epithelial (Hs578T) and the diploid myoepithelial (Hs578Bst) cell lines. , 1977, Journal of the National Cancer Institute.

[73]  J. Fogh,et al.  Absence of HeLa cell contamination in 169 cell lines derived from human tumors. , 1977, Journal of the National Cancer Institute.

[74]  M. Olivé,et al.  Breast tumor cell lines from pleural effusions. , 1974, Journal of the National Cancer Institute.

[75]  A. Long,et al.  A human cell line from a pleural effusion derived from a breast carcinoma. , 1973, Journal of the National Cancer Institute.

[76]  E Y LASFARGUES,et al.  Cultivation of human breast carcinomas. , 1958, Journal of the National Cancer Institute.

[77]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[78]  Ju-Hee Lee,et al.  Mechanisms of resistance to histone deacetylase inhibitors. , 2012, Advances in cancer research.

[79]  Marclippman.  The Effects of Estrogens and Antiestrogens on Hormone responsive Human Breast Cancer in Long-Term Tissue Culture , 2006 .

[80]  W. Voigt.  Sulforhodamine B assay and chemosensitivity. , 2005, Methods in molecular medicine.

[81]  Jelle J. Goeman,et al.  A global test for groups of genes: testing association with a clinical outcome , 2004, Bioinform..

[82]  Susumu Goto,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 2000, Nucleic Acids Res..

[83]  Hiroyuki Ogata,et al.  KEGG: Kyoto Encyclopedia of Genes and Genomes , 1999, Nucleic Acids Res..

[84]  S. Horwitz,et al.  Mechanism of action of taxol. , 1992, Trends in pharmacological sciences.

[85]  G. Trempe.  Human breast cancer in culture. , 1976, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.